What is Nuvora?
Nuvora, Inc. operates at the intersection of biotechnology and consumer health, specializing in the development and commercialization of advanced oral care products. The company is defined by its patented Sustained Release (SuRe) technology, a sophisticated delivery mechanism that allows for the prolonged release of active ingredients within the oral cavity. Its flagship portfolio includes Salese, a specialized lozenge engineered for dry mouth relief, and Dentiva, a solution focused on neutralizing odor-causing compounds to improve systemic oral hygiene. By addressing chronic conditions such as xerostomia and halitosis, Nuvora occupies a unique niche in the therapeutic oral care market, moving beyond traditional hygiene products toward functional, long-lasting health interventions.
How much funding has Nuvora raised?
Nuvora has raised a total of $31K across 1 funding round:
Debt
$31K
Debt (2021): $31K with participation from PPP
Key Investors in Nuvora
PPP
Public-Private Partnership
What's next for Nuvora?
With the recent infusion of capital, Nuvora is well-positioned to scale its manufacturing capabilities and broaden its distribution channels. The strategic focus will likely shift toward deepening market penetration for its SuRe-based product line and potentially exploring new therapeutic applications for its sustained-release platform. As the company matures, the emphasis will remain on clinical validation and expanding its reach within the professional dental and consumer retail sectors, ensuring that its innovative lozenge technology becomes a standard in oral health management. The current funding trajectory suggests a robust roadmap aimed at solidifying Nuvora's leadership in the specialized oral care segment.
See full Nuvora company page
